Jeena Sikho Lifecare (JSLL) Q4 25/26 earnings summary

Executive summary

• Consolidated FY26 revenue from operations was ₹80,136.39 lakh and net profit ₹22,169.81 lakh, versus ₹46,907.19 lakh and ₹7,994.33 lakh in FY25; audited results received unmodified opinions.

• FY26 growth was supported by higher patient volumes, wider service reach and product traction; total bed capacity reached 2,861, including 2,300 operational beds.

• Board recommended a final FY26 dividend of ₹4.50 per ₹2 face-value share, subject to shareholder approval.

Financial highlights

• Consolidated FY26 PBT was ₹29,739.35 lakh; diluted EPS was ₹17.81 versus ₹6.42 in FY25.

• Standalone FY26 revenue was ₹80,134.64 lakh and net profit ₹22,217.57 lakh; diluted EPS was ₹17.85 versus ₹6.42 in FY25.

• Consolidated Q4 FY26 revenue was ₹21,555.32 lakh and net profit ₹4,507.77 lakh, versus ₹13,925.06 lakh and ₹2,533.97 lakh in Q4 FY25.

• Q4FY26 standalone revenue was ₹21,555 lakh, up 55% YoY; EBITDA was ₹7,798 lakh, up 70%, and PAT was ₹4,535 lakh, up 79%.

• FY26 gross profit was ₹70,986 lakh, with an 89% gross margin; EBITDA was ₹34,963 lakh and EBIT ₹30,205 lakh.

Outlook and guidance

• Priorities include improving utilization at existing assets, launching centres and adding beds, expanding OTC sales, and broadening the product portfolio.

• Management expects cashless insurance and expanded Government Panel/AYUSH coverage to support volumes; overseas expansion is planned, beginning with the UAE.

• The 561 recently added beds and 445 beds in the pipeline are intended to strengthen capacity, regional reach and medium-term volume growth.

• Advance funding for a proposed 51% acquisition of Back to Roots Ayurveda by Dr. Shyam LLC remained subject to share-transfer and other regulatory formalities.